H.C. Wainwright still thinks Immunocore is a good buy but has cut its price target from $100 to $80.

IMCR · Immunocore

The AI's read

The Buy rating still shows confidence from this analyst, but the lower target points to a less favorable view of the share price. The report gives no new company results, so these opposing views do not change Immunocore's business outlook.